A Nurse-led Structured Risk Factor Management Programme to Improve Quality of Life for Patients With Atrial Fibrillation
Effects of a Nurse-led Structured Risk Factor Management Programme on Health-related Quality of Life, Symptom Burden and Cardiovascular Health in Patients With Atrial Fibrillation: A Randomised Controlled Trial
The goal of this clinical trial is to evaluate the effects of a nurse-led, structured risk factor management programme on health-related quality of life, symptom burden and cardiovascular health in adults with atrial fibrillation (AF).
AF is the most common heart rhythm disorder. It increase the risk of stroke, heart failure, and death. Its symptoms, including palpitation, fatigue, and breathlessness, often limit daily activities and reduce quality of life, even in patients receiving treatment to control heart rhythm or rate. in the proposed nurse-led program, the cardiac nurse will teach AF patients how to manage health habits that affect AF, including eating well, staying active, sleeping well, not smoking, drinking less alcohol, and taking medicines as prescribed. A nurse works with each person to set small, realistic goals.
The main questions it aims to answer are:
- Does the programme improve health-related quality of life for AF patients?
- Does the programme improve symptom burden for AF patients?
- Does the programme improve the functional exercise capacity for AF patients?
- Does the programme increase the reported self-efficacy level for participants?
- Does the programme improve the health behaviours, physiological risk parameters and cardiovascular health score for participants?
Researcher will compare interventional group (80 AF participants joining the 12-week program in addition to usual care) to a control group (80 AF participants receive usual care only) to see if the program works to improve the quality of life, symptom burden and overall cardiovascular health than usual care alone among AF patients.
Participants in the intervention group will:
- Receive a 1-hour face-to-face individual session with nurse for structured AF self-management education and personalized behavioural change planning in week 1
- Keep track of their own health behaviours using a self-management booklet
- Get 6 bi-weekly telephone follow-up calls from the nurse to review progress and support staged behavioural change
- Receive weekly tailored text messages with reminders and encouragement
The study will take place at three hospitals in Hong Kong and will enrol about 160 adults. Each person will take part for about 5 months. Researchers will evaluate outcome (quality of life, AF symptom severity, functional exercise capacity, self-efficacy, health behaviours, body mass index, blood pressure, blood cholesterol, blood sugar, Life Essential 8 score) at three timepoint: baseline, upon completion of the programme (12 week), and 8 weeks thereafter (20 week).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Atrial fibrillation (AF) is the most common sustained heart rhythm disorder. It increase the risk of stroke, heart failure, and death. Its symptoms, including palpitation, fatigue, and breathlessness, often limit daily activities and reduce quality of life, even in patients receiving treatment to control heart rhythm or rate. Comorbidity and risk factor contribute to the onset and progression of AF. International guidelines now recommend managing comorbidity and risk factors as a core pillar of AF care. However, translation into routine practice remains sub-optimal, characterized by brief, unstructured lifestyle counselling. This study is an assessor-blinded, parallel-group randomised controlled trial aiming to evaluate the effects of a nurse-led, structured risk factor management program on health-related quality of life, symptom burden, and cardiovascular health in AF patients, thereby informing secondary prevention of AF.
This study will be conducted in the specialist outpatient clinics of the cardiac units of three regional hospitals in Hong Kong. Eligible participants are adults aged ≥18 years who are (1) referred for management of symptomatic AF at the specialist outpatient clinic, (2) community-dwelling, (3) in possession of a smartphone, and (4) with at least one risk factor (hypertension, diabetes mellitus; BMI ≥23kg/m2; waist circumference ≥100cm for males or ≥90cm for females; dyslipidaemia; obstructive sleep apnoea; active smoking; alcohol use >3 standard drinks per week; and physical inactivity ). The sample size was estimated for the primary outcome of HRQoL at T1. Informed by two comparable nurse-led behavioural interventions and anticipating a medium effect, 64 participants per arm are required to detect an effect size of 0.5 with 80% power at a two-sided 5% significance level (G*Power 3.1.9.7). Applying a pooled baseline standard deviation of 18.6 points reported in a comparable Hong Kong AF population, this detects a between-group difference of 9.3 points on the primary HRQoL instrument, exceeding the 5-point minimal clinically important difference. Allowing for 20% attrition, 160 participants (80 per group) will be recruited. Participants will be randomly allocated in a 1:1 ratio to the intervention group (12-week nurse-led risk factor management programme in addition to usual care) or control group (usual care only).
Evaluation outcomes will be measured at baseline (T0), 12 weeks (T1), and 20 weeks (T2) thereafter. The primary outcome is health-related quality of life. Secondary outcomes include AF symptom severity, functional exercise capacity (distance walked in 6 minutes), self-efficacy, health behaviours (diet, physical activity, smoking status, sleep duration, alcohol consumption, and medication adherence), physiological parameters (body mass index, blood pressure, fasting lipid profile and fasting blood glucose), and overall cardiovascular health measured by the American Heart Association's Life Essential 8 score.
After double data entry, outcome analyses will be performed on an intention-to-treat basis. Normality of continuous variables will be assessed using the Shapiro-Wilk test to guide the choice between parametric and non-parametric methods. Baseline characteristics will be summarised as mean ± SD or median (IQR) for continuous variables and as frequencies and percentages for categorical variables, with baseline between-group homogeneity assessed using the independent t-test, chi-square test, or Mann-Whitney U test as appropriate. Primary analyses will employ generalised estimating equations (GEE) to examine between-group change across T0, T1, and T2, incorporating group and time as interaction terms and adjusting for a priori covariates (age, sex, AF type, AF duration, left atrial size, and left ventricular ejection fraction). Analyses will use IBM SPSS version 29.0, with a two-sided p-value < 0.05 considered statistically significant.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Kimmy Wai Ping Chan
- 電話番号:+852 55369048
- メール:kimmycwp10@connect.hku.hk
研究場所
-
-
-
Hong Kong、香港
- Princess Margaret Hospital, Prince of Wales Hospital and Tuen Mun Hospital
-
コンタクト:
- Kimmy Wai Ping Chan
- 電話番号:+852 55369048
- メール:kimmycwp10@connect.hku.hk
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Chinese adults aged ≥18 years who are referring for management of symptomatic paroxysmal or persistent AF at the specialist outpatient clinics
- Community-dwelling
- Possessed a smartphone
- Has the presence of at least one of the following risk factors: hypertension, diabetes mellitus; BMI ≥23kg/m2; waist circumference ≥100cm for males or ≥90cm for females; dyslipidaemia; obstructive sleep apnoea; active smoking; alcohol use >3 standard drinks per week; and physical inactivity (i.e. <150 minutes of moderate-to-vigorous physical activity per week, or an average of <8000 steps per day)
Exclusion Criteria:
- Cannot understanding Cantonese or reading Chinese,
- Has impaired communication
- Has psychiatric problems
- Has cognitive impairment (i.e. Abbreviated Mental Test ≤6)
- Has severe co-existing medical conditions (e.g. terminal illness).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Intervention group
The participants in the intervention group will receive a 12-week, structured, nurse-led risk factor management program for AF, in addition to the usual care at the study hospital. |
This program, grounded in the Information-Motivation-Behavioral Skills model and Social Cognitive Theory, is designed to improve AF self-management and support sustained modification of behavioral risk factors . Delivered by a registered nurse with cardiac specialty, this program comprises 4 components:
|
|
介入なし:Control group
The participants in the control group will receive the usual care provided by study hospital, comprising physician consultations and medication prescription at routine follow-up, without a structured risk factor management programme. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Health-related quality of life assessed by Atrial Fibrillation Effect on Quality-of-Life (AFEQT)
時間枠:At baseline, 12 weeks and 20 weeks
|
The 20-item AFEQT will be used to measure disease-specific health-related quality of life across four subscales: symptoms, daily activities, treatment concerns and treatment satisfaction. Each item is rated on a 7-point Likert scale. Raw scores are transformed to a 0-100 scale, with higher scores indicating better health status. |
At baseline, 12 weeks and 20 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
AF symptom severity assessed by Atrial Fibrillation Severity Scale (AFSS)
時間枠:At baseline, 12 weeks and 20 weeks
|
The 19-item AFSS will be used to assess patient-perceived AF symptom burden and severity. The instrument comprises two items on demographic characteristics, five items on AF disease burden (the frequency, overall severity and duration of symptomatic AF episodes), one item on global well-being, four items on AF-related healthcare utilization, and seven items on AF symptom severity. The seven AF symptom severity items are rated on a five-point Likert scale, yielding a total AFSS severity score ranging from 0 to 35, with higher scores indicating more severe symptoms. |
At baseline, 12 weeks and 20 weeks
|
|
Functional exercise capacity assessed by 6-minute Walk Test
時間枠:At baseline, 12 weeks and 20 weeks
|
The total distance walked in 6-minute walk test will be used to measure functional exercise capacity. Participants will be instructed to walk at their own pace along an uninterrupted 30-m corridor for 6 minutes with continuous heart rate monitoring. A longer distance indicates better functional exercise capacity. |
At baseline, 12 weeks and 20 weeks
|
|
Self-efficacy assessed by General Self-Efficacy Scale (GSE)
時間枠:At baseline, 12 weeks and 20 weeks
|
A 10-item GSE will be used to measure individual's perceived capability to cope with stressful or challenging situations. This scale was commonly used to predict individual's behaviour, goal intentions and self-regulatory commitments, which are central in health promotion. Each item on a 4-point Likert scale and summed, with higher score indicating greater self-efficacy. |
At baseline, 12 weeks and 20 weeks
|
|
Health behaviour: Dietary pattern assessed by Mediterranean Diet Scale (MDS) Questionnaire
時間枠:At baseline, 12 weeks and 20 weeks
|
A 13-item MDS Questionnaire will be used to assess self-reported adherence to Mediterranean dietary pattern. Each item is rated dichotomously (yes/ no) and summed, with higher score indicating greater adherence. |
At baseline, 12 weeks and 20 weeks
|
|
Health behaviour: Physical activity level assessed by International Physical Activity Questionnaire-short form (IPAQ-SF)
時間枠:At baseline, 12 weeks and 20 weeks
|
The 7-item IPAQ-SF will be used to measure self-reported physical activity over the past week across four domains: vigorous activities, moderate activities, walking and sitting.68 Scores are expressed in metabolic equivalent of task (MET)-minutes per week, where higher values indicate higher energy expenditure. |
At baseline, 12 weeks and 20 weeks
|
|
Health behaviour: Smoking status
時間枠:At baseline, 12 weeks and 20 weeks
|
Smoking status will be assessed by self-reporting cigarette use |
At baseline, 12 weeks and 20 weeks
|
|
Health behaviour: Sleep duration
時間枠:At baseline, 12 weeks and 20 weeks
|
Sleep duration will be assessed by self-reporting average hours of sleep per night |
At baseline, 12 weeks and 20 weeks
|
|
Health behaviour: Alcohol consumption level assessed by Alcohol Use Disorders Identification Test- Concise (AUDIT-C)
時間枠:At baseline, 12 weeks and 20 weeks
|
The 3-item AUDIT-C, a concise version of AUDIT, will be used to assess self-reported alcohol use across frequency of use, quantity of use, and frequency of health drinking. Each item is scored from 0 to 4 points, yielding a total score 0-12 with higher scores indicating greater alcohol use. |
At baseline, 12 weeks and 20 weeks
|
|
Health behaviour: Medication adherence assessed by Medication Adherence Report Scale (MARS-5)
時間枠:At baseline, 12 weeks and 20 weeks
|
The 5-item MARS-5 will be used to assess self-reported unintentional and intentional medication adherence. Each item is rated on a 5-point Likert scale and summed, with higher score indicating better adherence. |
At baseline, 12 weeks and 20 weeks
|
|
Physiological risk parameter: Body mass index
時間枠:At baseline, 12 weeks and 20 weeks
|
Body mass index will be calculated as dividing body weight (kilogram) by body height (meter) squared . Body weight and height are measured by a calibrated scale and stadiometer respectively. |
At baseline, 12 weeks and 20 weeks
|
|
Physiological risk parameter: Systolic and diastolic blood pressure
時間枠:At baseline, 12 weeks and 20 weeks
|
Systolic and diastolic blood pressure will be measured using a digital automatic blood pressure monitor with an appropriate size cuff. Participants will be asked to relax and sit quietly for 3-5 minutes before the blood pressure measurement. They will be seated with their arm supported at heart level for the measurement. |
At baseline, 12 weeks and 20 weeks
|
|
Physiological risk parameter: Fasting blood glucose
時間枠:At baseline, 12 weeks and 20 weeks
|
A fasting blood glucose will be assessed by a validated point-of-care device (BioHermes GluCoA1c) using a capillary blood sample obtained from a finger stick after 8 hours of fasting. |
At baseline, 12 weeks and 20 weeks
|
|
Physiological risk parameter: Fasting lipid profile
時間枠:At baseline, 12 weeks and 20 weeks
|
A portable point-of-care analyser (VivaDiag Lipid Testing System) will be used to measure circulating cholesterol (total cholesterol, low-density lipoprotein [LDL], high-density lipoprotein [HDL], triglycerides [TG]). Approximately 10uL of capillary blood sample will be collected at each measurement. |
At baseline, 12 weeks and 20 weeks
|
|
Life's Essential 8 (LE8) Composite Score
時間枠:At baseline, 12 weeks and 20 weeks
|
LE8 is a cardiovascular health score. It comprises 8 components: diet (MDS score) , physical activity (minute of moderate-intensity activity per week), nicotine exposure (self-reported use of cigarettes), sleep health (average hours of sleep per night), body mass index (kilogram/ meter^2), blood lipids (non-HDL cholesterol), blood glucose (fasting blood glucose or HbA1c for diabetes) and blood pressure (systolic and diastolic blood pressure). Each LE8 components are scored on a scale of 0 to 100 points, allowing generation of a composite cardiovascular health score which is the unweighted average of all components. Total scores range from 0 to 100 points. Higher scores correspond to better cardiovascular health. |
At baseline, 12 weeks and 20 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- CIRB-2026-557-5
- 2026.572 (その他の識別子:The Joint CUHK-NTEC Clinical Research Ethics Committee)
- HKWC-2026-527 (その他の識別子:Institutional Review Board of HKU/ HA HKW)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。